Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 14/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | PPID | Q08752 | 1/20 | 0.35 |
| ▸ | F11 | P03951 | 3/20 | 0.35 |
| ▸ | TPSB2 | P20231 | 3/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | F7 | P08709 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21437824 | 0.95 | CFD (0.41) | CFDBRD4CREBBPCD274PPID | |
| SCHEMBL21455588 | 0.94 | CFD (0.43) | CFDBRD4CREBBPPPIDF11 | |
| SCHEMBL21439647 | 0.94 | CFD (0.40) | CFDBRD4CREBBPPDCD1CD274 | |
| SCHEMBL21439481 | 0.94 | CFD (0.40) | CFDBRD4CREBBPPDCD1CD274 | |
| SCHEMBL21455922 | 0.93 | CFD (0.39) | CFDBRD4CREBBPPDCD1CD274 | |
| SCHEMBL21439213 | 0.93 | CFD (0.41) | CFDBRD4CREBBPPDCD1CD274 | |
| SCHEMBL23617048 | 0.93 | CFD (0.42) | CFDBRD4CREBBPPDCD1CD274 | |
| SCHEMBL21455551 | 0.92 | CD274 (0.40) | CFDBRD4CREBBPPDCD1CD274 | |
| SCHEMBL21439664 | 0.92 | CFD (0.40) | CFDBRD4CREBBPF11TPSB2 | |
| SCHEMBL21455534 | 0.92 | CFD (0.40) | CFDBRD4CREBBPPDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | CFD 17/4885BRD4 1106/4885CREBBP 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.